We are live on ! Find out more
EVMN

Evommune Inc
EVMN

84 hedge funds and large institutions have $793M invested in Evommune Inc in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

270% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 10

136% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 11

70% more capital invested

Capital invested by funds: $466M → $793M (+$328M)

42% more funds holding

Funds holding: 59 → 84 (+25)

9.71% more ownership

Funds ownership: 86.29% → 96% (+9.7%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
84
Holders Change
+25
Holders Change %
+42.37%
% of All Funds
1.03%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
37
Increased
26
Reduced
11
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$30.4M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$20.3M
3
BBA
Baker Bros. Advisors
New York
+$19.2M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$16.4M
5
BlackRock
BlackRock
New York
+$12M

Top Sellers

Rank Fund Capital Flow
1
Aberdeen Group
Aberdeen Group
United Kingdom
-$8.99M
2
OCA
Octagon Capital Advisors
New York
-$8.06M
3
SI
Sofinnova Investments
California
-$2.62M
4
Marshall Wace
Marshall Wace
United Kingdom
-$2.45M
5
SFM
Sphera Funds Management
Israel
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
26
Federated Hermes
Pennsylvania
$7.47M – – –
GPP
27
Great Point Partners
Connecticut
$7.47M – – –
UBS Group
28
UBS Group
Switzerland
$6.86M +$6.67M +294,961 +8,640%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$5.72M +$3.14M +138,830 +126%
EFM
30
E Fund Management
China
$5.6M +$5.51M +243,700 New
IHAM
31
Integral Health Asset Management
New York
$5.17M +$2.26M +100,000 +80%
SC
32
Stempoint Capital
New York
$4.39M +$2.84M +125,581 +184%
NCM
33
NEXTBio Capital Management
California
$4.23M -$1,000K -44,223 -19%
ACM
34
ADAR1 Capital Management
Texas
$4.23M – – –
State Street
35
State Street
Massachusetts
$4.13M +$3.35M +148,011 +470%
MIM
36
Monashee Investment Management
Massachusetts
$4.12M -$88.1K -3,899 -2%
SGM
37
Seven Grand Managers
New York
$3.79M +$2.03M +89,670 +120%
Goldman Sachs
38
Goldman Sachs
New York
$3.55M +$2.09M +92,648 +150%
OCA
39
Octagon Capital Advisors
New York
$3.3M -$8.06M -356,528 -71%
BOCH
40
Blue Owl Capital Holdings
New York
$2.3M +$2.26M +100,000 New
Charles Schwab
41
Charles Schwab
California
$2.18M +$729K +32,244 +51%
ECM
42
ExodusPoint Capital Management
New York
$2.16M +$2.12M +93,913 New
Ameriprise
43
Ameriprise
Minnesota
$2.1M -$297K -13,126 -13%
Northern Trust
44
Northern Trust
Illinois
$1.83M +$1.29M +57,119 +252%
SFM
45
Sphera Funds Management
Israel
$1.8M -$1.99M -87,913 -53%
VFT
46
Vanguard Fiduciary Trust
Pennsylvania
$1.67M +$1.64M +72,582 New
VPM
47
Vanguard Portfolio Management
Pennsylvania
$1.4M +$1.38M +60,993 New
PBM
48
Propel Bio Management
California
$1.28M +$1.26M +55,664 New
EP
49
Eversept Partners
New York
$1.26M +$1.24M +54,680 New
Hudson Bay Capital Management
50
Hudson Bay Capital Management
Connecticut
$1.18M +$1.16M +51,364 New
1
2
3 4

EVMN Hedge Fund Activity: Q1 2026 in Review

84 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Evommune Inc (EVMN) for Q1 2026, worth a combined $793M — up 70% from $466M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new EVMN positions and 10 closed out — a net gain of 27 holders — while 26 added to existing stakes and 11 trimmed.

The largest buyer was MPM BioImpact, adding an estimated $30.4M. The largest seller was Aberdeen Group, exiting entirely with an estimated $8.99M sold.

  • 84 institutional investors held Evommune Inc (EVMN) as of Q1 2026, up from 59 in Q4 2025.
  • Funds reported $793M of Evommune Inc stock for Q1 2026, up 70% quarter-over-quarter.
  • 37 funds opened new Evommune Inc positions in Q1 2026 and 10 closed out, a net change of +27 holders.
  • The largest Evommune Inc buyer in Q1 2026 was MPM BioImpact, an estimated $30.4M added.
  • The largest Evommune Inc seller in Q1 2026 was Aberdeen Group, an estimated $8.99M sold.

Based on aggregated 13F filings for Q1 2026.